Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
Read More
Tag: Visible 1
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
